Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Your Article Summary
See Latest Articles30 Years of Pharmaceutical Cost-Utility Analyses: Growth, Diversity and Methodological Improvement
PharmacoEconomics, 10/13/09
Neumann PJ et al. – The number of published pharmaceutical CUAs has grown steadily and accounts for almost half of all published CUAs. Adherence to good methodological practices does not appear to differ by study sponsor. Ratios from industry–sponsored studies are more favourable than other ratios. The results highlight that there are many opportunities for efficient healthcare investment, among pharmaceutical and non–pharmaceutical interventions, just as there are many investments that are inefficient.
Related Articles
Economic Evaluation and Cost-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation
PharmacoEconomics, 10/07/09
Relevance Score: 67%
Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings
Health Policy and Planning, 10/21/09
Relevance Score: 65%
Weighting Must Wait: Incorporating Equity Concerns into Cost-Effectiveness Analysis May Take Longer than Expected
PharmacoEconomics, 11/17/09
Relevance Score: 64%
Financial Risk of the Biotech Industry versus the Pharmaceutical Industry
Applied Health Economics and Health Policy, 10/20/09
Relevance Score: 64%
Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
PharmacoEconomics, 10/13/09
Relevance Score: 64%
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics
Journal of Clinical Pharmacy and Therapeutics, 03/19/10
Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis
PharmacoEconomics, 03/16/10
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren
European Journal of Clinical Pharmacology, 03/16/10
Article Search
Sponsor
Sponsor